Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 23Leukemia 13Leukemia, Myeloid, Chronic-Phase 11Gastrointestinal Stromal Tumors 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 4Neoplasms 3Neoplasm Metastasis 3Melanoma 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Myeloid 3Blast Crisis 3Thyroid Neoplasms 2Prostatic Neoplasms 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Bone Marrow Diseases 2Uterine Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thrombocytosis 1Thrombocythemia, Essential 1

Interventions

vandetanib 2rovalpituzumab tesirine 1pentetreotide 1lenvatinib 1cabozantinib 1Sorafenib 1Octreotide 1Lithium Carbonate 1Irinotecan 1Imatinib Mesylate 1Dexamethasone 1Dacarbazine 1Capecitabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Medullary × Imatinib Mesylate × Clear all
NCT00354523 2014-12-17

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
21 enrolled
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡